Table of Contents
- A Lab in a Box: Turning Stool Samples Into Health Signals
- From Prevention to Prescription: The Business of the Microbiome
A Lab in a Box: Turning Stool Samples Into Health Signals
For decades, medicine has largely been reactive diagnosing disease after symptoms appear and prescribing treatment once damage is done. In a modest laboratory in Bengaluru, a team of scientists is betting that the future of healthcare lies in reversing that equation.
Founded in 2014 by Debojyoti Dhar and Kumar Sankaran, Leucine Rich Bio is building its business on a premise that once belonged mostly to academic journals: that the trillions of microorganisms living inside the human gut may hold early warnings and solutions for chronic disease.
Their flagship test, BugSpeaks, arrives in a discreet at-home kit. Customers provide a stool sample, ship it to the company’s Bengaluru lab, and weeks later receive a report assigning them a “Rich Index Score” — a composite marker of microbial diversity and balance. Lower diversity, researchers increasingly believe, is associated with metabolic disorders, inflammation and weakened immunity.
Behind the scenes, the process resembles genomic research more than a routine diagnostic. Scientists extract microbial DNA and run it through next-generation sequencing machines, decoding strings of A, T, G and C the four nucleotides that form genetic instructions. The patterns reveal which bacteria, fungi and viruses inhabit the gut, and in what proportions.
But raw data is not the product. The company translates sequencing results into a three-month personalised diet plan designed to increase beneficial microbes and suppress harmful ones. Unlike genes, Dhar notes, the microbiome is modifiable. “Food,” he often says, “is the most powerful intervention.”
The test, priced at ₹10,000, targets consumers over 40 managing lifestyle conditions, as well as younger urban Indians drawn to longevity and preventive wellness. The report maps vitamin synthesis potential, short-chain fatty acid production and even antibiotic resistance patterns metrics that once remained confined to research institutions.
Leucine Rich Bio has since expanded into skin microbiome testing and plans to introduce oral and vaginal microbiome analyses. Under its supplement brand, RychBiome, it offers personalised probiotics and topical products informed by individual microbial data.
The promise is alluring: what if the bacteria in your gut could tell you not only what to eat but how to avoid diabetes, fatty liver disease or hypertension?
From Prevention to Prescription: The Business of the Microbiome
The company’s ambitions extend well beyond diet charts. In a registered clinical trial involving patients with Type 2 diabetes, participants who followed BugSpeaks’ dietary recommendations alongside medication saw a reported 20 percent reduction in HbA1c levels over three months a marker of long-term blood glucose control. Inflammation and blood pressure indicators also declined. The findings were published in 2024.
Further trials are underway, including a collaboration with AIIMS Raipur exploring whether microbiome-based nutrition can improve quality of life in cancer patients undergoing chemotherapy.
For now, the tests are positioned as wellness tools rather than diagnostic devices. But the long-term vision is unmistakably clinical even pharmaceutical. The founders speak openly about drug discovery as the next frontier, citing growing scientific consensus that microbial imbalance, or dysbiosis, plays a role in numerous chronic conditions.
The business model reflects that scale of ambition. Revenue flows not only from direct-to-consumer sales but also from partnerships with hospitals, diagnostic chains and FMCG companies seeking microbiome insights to refine product development. International collaborations now extend to the Philippines, Brazil and the Middle East, where the company has established a Dubai-based entity to serve the GCC region.
The global microbiome analysis market, valued at over $1 billion in 2024, is projected to nearly double by 2030. Competitors such as Viome Life Sciences and Microba have already positioned themselves in Western markets. Leucine Rich Bio’s differentiator, its founders argue, is its growing proprietary database of Indian microbiome profiles more than 20,000 samples analysed to date.
Unlike many venture-backed biotech startups, the company has remained largely bootstrapped, raising early angel funding but delaying institutional capital while validating its science.
Whether microbiome science ultimately reshapes mainstream medicine remains an open question. But as preventive healthcare gains traction in India’s expanding middle class, the notion that the path to better health begins not in a hospital ward but in the gut no longer sounds fringe.
If Leucine Rich Bio’s founders are right, tomorrow’s prescriptions may begin with a simple question: what, exactly, is living inside you?
About the Author,
Swasti Jain,
Management student and Intern at hostelbee.com
Follow her:
Leave a Reply